Bharat Parenterals Q1 FY27: Better gross margins, but profits still held back by the Innoxel build-out

Bharat Parenterals Limited opened FY27 with a mixed quarter. Consolidated revenue for Q1 FY27 came in at 93.7 crore, down 19.2% year on year. Consolidated EBITDA was 8.5 crore, with a 9.1% margin versus 11.9% in Q1 FY26. The group reported a consolidated loss of 3.6 crore for the quarter.

Management’s core explanation is that the revenue decline is not broad-based. It attributes the fall to the standalone business being compared against what it calls the largest revenue quarter in the company’s history, linked to a 210 crore institutional order where the opening tranche in Q1 FY26 is being compared with the closing tranche in Q1 FY27. In other words, the quarter reflects a contract lifecycle comparison rather than a sharp demand shock.

More importantly, management argues that the quarter changed the quality of revenue more than the quantity. It states that consolidated gross profit stayed flat at 47.4 crore, while gross margin expanded by around 1,000 basis points to 50.6%. This is one of the strongest signals in the presentation, because it suggests that the parts of the book that did not repeat were lower-margin in nature.

Consolidated performance: revenue down, opex up, mix improving

The consolidated P&L table shows operating revenue of 94.8 crore in Q1 FY27 versus 117.1 crore in Q1 FY26. EBITDA declined to 8.5 crore from 13.8 crore, while PAT moved to -3.6 crore from -0.9 crore.

Management pins the EBITDA decline on operating expenses. It states that opex increased 16.5% year on year to 38.9 crore and that this higher cost base sits largely in the subsidiaries, Innoxel Lifesciences and Varenyam Healthcare, which are building ahead of contracted forward revenue.

A key structural shift is also visible in the revenue composition across the group. Management states that Innoxel and Varenyam Healthcare now contribute 46% of consolidated revenue before eliminations, versus 21% a year ago. That matters because both subsidiaries are positioned differently from the legacy export formulation base and are expected to scale faster if execution holds.

Sum-of-parts view: profits in the base business, losses in the growth engine

The presentation’s most investor-useful disclosure is the entity-level bridge. In Q1 FY27, the standalone BPL business reported revenue of 55.5 crore and EBITDA of 6.8 crore, a 12.3% margin. Varenyam Healthcare reported 25.1 crore revenue and 3.1 crore EBITDA, a 12.4% margin. Innoxel reported revenue of 21.4 crore, but EBITDA of -1.8 crore and PAT of -10.4 crore.

This makes the group’s near-term financial dynamic straightforward: the legacy export formulation platform is profitable, Varenyam Healthcare is now generating operating profits with scale, and Innoxel is still the largest drag on consolidated earnings.

BPL Standalone: a tender-driven base with branded strength and available capacity

For the standalone business, Q1 FY27 revenue was 55.5 crore versus 94.4 crore in Q1 FY26, a 41.2% decline. However, sequentially the business was stable versus Q4 FY26 revenue of 56.5 crore. EBITDA margin rebounded to 12.3% from 0.1% in Q4 FY26.

The presentation also discloses the standalone revenue mix: branded 81% and tender 19%. For investors tracking volatility, this split is useful because tender and institutional order tranches can distort quarterly comparisons.

Operationally, BPL highlights its presence across 40+ countries, 350+ product filings, and an order book of 171 crore comprising 119 crore domestic tenders, 33 crore exports and 20 crore international tenders. It also lists planned FY27 capex of 15 crore.

Capacity disclosures suggest headroom. The general block utilisation is shown at 48.5%, while beta-lactam and cephalosporin blocks are at 21% and 24.3% utilisation respectively. If demand and registrations build, the business does not appear capped by near-term physical capacity.

Innoxel: regulatory platform in place, commercial supply is the FY27 inflection point

Innoxel Lifesciences is framed as the group’s growth engine. In Q1 FY27, it delivered 21.4 crore revenue, up 165% year on year, but EBITDA remained negative at -1.8 crore and PAT at -10.4 crore.

The operating commentary leans heavily on regulatory milestones already achieved. Innoxel received a USFDA Establishment Inspection Report for an inspection conducted Apr 28 to May 2, 2025. It also completed an EU-GMP inspection by Belgium’s FAMHP with zero critical or major observations. The company positions this as commercial-supply enabling for the US and select EU markets.

The key forward marker is the start of commercial CMO supply from Q2 FY27. The presentation also states a FY27 plan that includes 14 filings (6 own and 8 CMO), a deal target of 20 in the year, and indicates that the first own CDDO product is expected in Q3 FY28.

Financially, Innoxel also carries explicit guidance. For FY27, it guides 35% to 45% revenue growth and 20% to 25% EBITDA margin, along with out-licensing revenue expected at 70 to 90 crore. Execution against this will be central to whether consolidated profitability turns sustainably positive.

Varenyam Healthcare: institutional branded generics scaling with improving leverage

Varenyam Healthcare, the group’s domestic institutional branded generics subsidiary, delivered one of the clearest positives in the quarter. Q1 FY27 revenue was 25.1 crore, up 52.2% year on year, and EBITDA margin expanded to 12.4%.

The operating model is described through field force metrics and hospital reach. The company reports 211 medical representatives, with a target of 250 by FY27. It also discloses a PCPM (per MR per month) figure of 3.82 lakh and indicates this as a driver of operating leverage. Distribution infrastructure includes 10 owned depots across 26 states and 800+ channel partners, with 2 to 3 additional depots planned in FY27.

The presentation also provides brand concentration metrics. It states that the top 5 brands contributed 49.4% of revenue, and the largest brand, Sugmadex (Sugammadex 100 mg/ml), contributed 17.5%.

Varenyam Bio: long-dated option with disclosed timelines

Varenyam Bio Lifesciences remains pre-revenue. In Q1 FY27 it reported CWIP of 33.22 crore against a 160 crore project budget, with borrowings of 7.12 crore and net worth of 28.22 crore. The quarter’s EBITDA loss is small at 0.09 crore, reflecting early-stage operating costs.

The project roadmap is clearly stated: commissioning in Sep 2027, line validation in Mar 2028, first filing in Q1 FY29 and first commercial supply in Q4 FY29. The facility is positioned as an EU-GMP targeted platform addressing emerging regulated markets, with focus markets listed as Brazil, Colombia, Mexico, South Africa, Australia, and the EU.

What to track from here

Bharat Parenterals enters FY27 with explicit guidance across each operating entity. Standalone BPL guides 10% to 15% growth and 10% to 15% EBITDA margin. Varenyam Healthcare guides 20% to 25% growth and 8% to 13% EBITDA margin, while Innoxel guides 35% to 45% growth and 20% to 25% EBITDA margin.

Q1 FY27 shows that the group can expand gross margins even when top-line is volatile, but consolidated earnings are still sensitive to the cost and ramp profile of Innoxel. The start of commercial CMO supply from Q2 FY27 is presented as the most important near-term catalyst. If that ramp translates into EBITDA break-even and then positive operating leverage at Innoxel, the group’s consolidated financial profile could look materially different in the second half of FY27.